Henan Taloph Pharmaceutical Stock Co.,Ltd Provides Earnings Guidance for the Fiscal 2019
January 20, 2020
Share
Henan Taloph Pharmaceutical Stock Co.,Ltd provided earnings guidance for the fiscal 2019. According to preliminary statistics of its financial department, the Company will turn losses into gains in its the net profit belonging to shareholders of the listed company in 2019 compared with the same period of the year before, with the net profit belonging to shareholders of the listed company to be between RMB 42 million and RMB 50 million. The net profit belonging to shareholders of the listed company after excluding extraordinary profit and loss will be between RMB 25.3 million and RMB 33.3 million.
Henan Taloph Pharmaceutical Stock Co Ltd is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company operates four segments. Pharmaceutical Manufacturing segment is mainly engaged in pharmaceutical preparations and Chinese herbal medicine slices business. Its products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, Xiaoer Qingre Zhike oral liquid, Xiaoer Tuire oral liquid, Danshen oral liquid, Shengmaiyin, Fufang Yimu oral liquid, and various Chinese herbal medicine slices. Pharmaceutical and Medicinal Materials Circulation segment is mainly engaged in fresh processing business and traceable medicinal materials trading. Pharmaceutical Research and Development Services segment mainly provides technical services such as preclinical pharmaceutical research, clinical contract research organization (CRO) research, and registration application. Other segment is mainly engaged in investment business.
HENAN TALOPH PHARMACEUTICAL STOCK CO.,LTD 
